Peripheral Neuropathy Market Size
According to the latest market report published by Credence Research, Inc. “Peripheral Neuropathy Market – Growth, Future Prospects, and Competitive Analysis, 2017 – 2025,” the global peripheral neuropathy market was valued at US$ 1,470.9s Mn in 2016, and is expected to reach US$ 1,998.8 Mn by 2025, expanding at a CAGR of 3.2% from 2017 to 2025.
Browse the full report Peripheral Neuropathy Market – Growth, Future Prospects and Competitive Analysis, and Forecast, 2017 – 2025 report at http://www.credenceresearch.com/report/peripheral-neuropathy-market
Peripheral neuropathy mainly causes due to damage occurred to peripheral nerves resulting in weakness, numbness, and usually in hands and feet. Peripheral neuropathy is caused due to traumatic injuries, infections, metabolic problems, inherited causes and exposure to toxins, and most commonly by diabetes mellitus. According to the World Health Organization (WHO), it was estimated that there would be 285 million diabetics by 2010 in the world. This estimate is projected to increase by 65% to become 438 million in the year 2030. Thus, rising prevalence of diabetes mellitus is expected to increase the population of patients suffering from peripheral neuropathy. With a limited number of prescription drugs available for neuropathic pain, off-label prescription of several other drugs is widespread. The pharma industry has been struggling to further improve the currently available therapeutic options due to the complexity of identification of the most suitable targets for investigation. Recently, there has been a shift towards the adoption of transdermal therapies for the management of neuropathic pain.
The global peripheral neuropathy market is segmented by treatment type as pharmacological therapies and non-pharmacological therapies. Pharmacological therapies includes pain killers, anti-seizures medication, antidepressants. Non pharmacological therapies include transcutaneous electrical nerve stimulation, plasma exchange and intravenous immune globulin and others (physical therapy and surgery). Pharmacological therapies most commonly used and dominates the peripheral neuropathy market, while non-pharmacological therapies are used along with other treatment options.
In the base 2016, North America was observed as the largest market for peripheral neuropathy. The rising geriatric population, growing incidences of diabetes in the region is the prime factor driving the North America peripheral neuropathy market. Asia Pacific is anticipated to be fastest growing market for the forecast period 2017-2025.
Market Competition Assessment:
Key players in the global peripheral neuropathy market are
Abbott Laboratories, Bristol Myers Squibb, Cipla Limited, Eli Lilly and Company, GlaxoSmithKline plc, Lupin Limited, Merck and Co. Inc., Novartis, Pfizer Inc, Dr. Reddy’s Laboratories
Key Market Movements:
- Prediabetes and diabetes both are becoming a bigger problem and as a consequence more and more patients are anticipated to suffer from peripheral pain. As the prevalence of this condition persists to grow, the demand for treatment for peripheral neuropathy will also correspondingly increase.
- Non-pharmacologic treatments of neuropathic pain are usually begun simultaneously with pharmacologic regimen. It is reported through various studies that reference for non-pharmacologic methods for neuropathic pain management is on a perpetual rise.
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.
Who we are
Credence Research is a worldwide firm, containing more than 15 research consultants and almost 100 research and information professionals.
Our customers mirror our worldwide nature. Around 45% are in Europe, 30% in the Americas, 13% in Asia Pacific and 12% in the Middle East and Africa.
Our firm is intended to work as one. We are a solitary global research organization united by a solid arrangement of qualities, concentrated on customer effect.
What we do
We serve customers at each level of their organization, in whatever limit we can be most helpful, whether as a trusted counsel to top management or as a hands-on mentor for forefront representatives. For each engagement, we collect a group with the most suitable experience and ability.
No matter the challenge, we concentrate on delivering functional and persevering results and preparing our customers to develop and lead. We join forces with customers to place suggestions into practice. Our research specialist works straightforwardly with customers over long stretches to create workforce aptitudes, drive operational change, and apply new working strategies.
Name: Chris Smith
Designation: Global Sales Manager